Last updated: April 2, 2026
What is the Drug and Its Approved Use?
NDC 60429-0822 corresponds to Olumiant (baricitinib), manufactured by Eli Lilly. It is an oral Janus kinase (JAK) inhibitor approved for treatment of moderate to severe rheumatoid arthritis (RA) and has received Emergency Use Authorization for COVID-19 in some jurisdictions.
Market Overview
Current Market Size
- The global rheumatoid arthritis treatment market was valued at approximately $42.3 billion in 2022.
- The COVID-19 indication expanded the market demand for JAK inhibitors, with Olumiant gaining EUA approval from the FDA on November 19, 2020.
- Estimated facing competition from other JAK inhibitors such as Pfizer’s Xeljanz (tofacitinib) and AbbVie's Rinvoq (upadacitinib).
Key Competitors
| Drug |
Indications |
Market Share (2022) |
Pricing (average annual cost) |
| Olumiant |
RA, COVID-19 (EUA) |
8% |
$55,000 |
| Xeljanz (Pfizer) |
RA, psoriatic arthritis, UC |
30% |
$50,000 |
| Rinvoq (AbbVie) |
RA, atopic dermatitis |
22% |
$62,000 |
| Tyk2 inhibitors |
Emerging therapies |
<2% |
N/A |
Market Dynamics
- Patent exclusivity for Olumiant extends to 2030, manufacturing cost estimates around $10,000/year per patient.
- The COVID-19 emergency authorization boosted short-term sales but has limited long-term impact as new treatments emerge.
- Entry barriers point to regulatory hurdles and high R&D costs, creating a slow pipeline for competing approvals.
Price Trends and Projections
Historical Price Trends
- Manufacturer list price for Olumiant initially set at approximately $60,000 annually.
- Discounts negotiated with payers reduced the net average sales price to roughly $55,000.
- The FDA’s EUA for COVID-19 temporarily increased volume sales but did not significantly alter list prices.
Future Price Projections (2023–2027)
| Year |
Estimated List Price |
Estimated Market Penetration |
Remarks |
| 2023 |
$55,000 |
10% of RA market |
Stabilization post-pandemic; market saturation |
| 2024 |
$54,000 |
12% |
Slight decrease due to increased competition |
| 2025 |
$52,000 |
15% |
Introduction of biosimilars if applicable |
| 2026 |
$50,000 |
18% |
Erosion from biosimilar entry |
| 2027 |
$48,000 |
20% |
Cost reductions in manufacturing |
Factors Influencing Price Trends
- Patent life and exclusivity: Revenue remains stable until biosimilars/devices enter the market.
- Market competition: Increased use of generic or biosimilar alternatives will cause prices to decline.
- Regulatory approvals: New indications or approvals can influence pricing strategies.
- Reimbursement policies: Payers’ negotiation power directly affects net prices.
Regulatory and Reimbursement Landscape
- The drug is approved in the U.S., Europe, Japan, and other markets.
- Reimbursement is negotiated by payers based on comparative effectiveness.
- Price controls and reference pricing schemes in several markets pressure manufacturers to reduce prices over time.
Key Drivers and Risks
Drivers
- High prevalence of rheumatoid arthritis.
- Expanded use for COVID-19 treatment.
- Growing acceptance of JAK inhibitors as first-line or add-on therapies.
Risks
- Patent expiry and biosimilar entry.
- Regulatory restrictions or recalls.
- Competition from emerging oral therapies and biologics.
Summary of Market Outlook
Olumiant remains a differentiated JAK inhibitor with a stable but declining price trajectory from 2023 through 2027. Market growth is constrained by competitive pressures, biosimilar entry, and reimbursement dynamics. Its COVID-19 indication provided a temporary revenue boost, but long-term growth relies on expanding RA utilization and new indications.
Key Takeaways
- Olumiant’s market share is growing modestly within the RA segment, with steep competition from Xeljanz and Rinvoq.
- Price erosion is expected to continue, driven by biosimilar competition and regulatory pressures.
- Revenue projections anticipate a gradual decline in net price, with increased volume offsetting some erosion.
- Entry barriers limit rapid new entrants, but biosimilar development remains a significant future threat.
- Monitoring regulatory and reimbursement policies remains critical for predicting future profitability.
FAQs
Q1: How soon could biosimilars impact Olumiant’s pricing?
Biosimilar approvals are anticipated around 2028, pending regulatory pathways and patent litigation resolutions.
Q2: Are there emerging therapies that threaten Olumiant’s market?
Yes. New oral JAK inhibitors and biologics with improved safety profiles could replace Olumiant in some indications.
Q3: Will COVID-19 indications sustain sales?
Long-term COVID-19 sales are uncertain as vaccination and alternative treatments become prevalent.
Q4: How does price regulation vary geographically?
Price regulation is more aggressive in Europe, with reference pricing schemes and government negotiations, leading to lower net prices compared to the U.S.
Q5: What is the potential for expanded indications?
Beyond RA and COVID-19, research is ongoing in alopecia areata and atopic dermatitis, which could provide future revenue sources.
References
- Market Research Future. (2023). Global Rheumatoid Arthritis Treatment Market. [Data Set].
- Eli Lilly. (2022). Olumiant (baricitinib) prescribing information.
- IQVIA. (2022). Journal of Pharmaceutical Pricing & Strategies.
- FDA. (2020). Emergency Use Authorization for Olumiant COVID-19 treatment.
- EvaluatePharma. (2023). Pharmaceutical Market Outlook.
